Pravara Rural College of Pharmacy, Pravarangar, Loni, Maharashtra, India -413736
Polycystic ovary syndrome (PCOS) is a multifaceted endocrine disorder prevalent among women of reproductive age globally. Its pharmacological and therapeutic management has evolved considerably in recent years, reflecting deeper insights into its intricate pathophysiology. Conventional interventions—such as insulin sensitizers, ovulation inducers, and anti-androgens—remain the foundation of treatment, primarily targeting metabolic disturbances and reproductive dysfunctions. However, these options are limited by variable efficacy, adverse effects, and the absence of individualized therapeutic protocols. Recent advances emphasize emerging therapies, including novel drug classes, nutraceutical formulations, and integrated lifestyle interventions that collectively address metabolic, reproductive, and psychological components of the disease. Despite their promise, most new strategies are constrained by insufficient high-quality clinical evidence, overreliance on data extrapolated from non-PCOS populations, and incomplete mechanistic understanding. Current research underscores the necessity for precision medicine—leveraging genetic, molecular, and digital health data—to enable personalized and targeted therapy frameworks. Future progress will hinge on rigorous randomized controlled trials and multidisciplinary collaboration aimed at refining current pharmacological regimens and validating integrative therapies. A multimodal, patient-centered approach that aligns treatment strategies with individual pathophysiological profiles offers the greatest potential to optimize outcomes and manage the complex interplay of hormonal, metabolic, and emotional dimensions of PCOS.
Polycystic ovary pattern (PCOS) is a current endocrine complaint affecting women of reproductive age, characterized by a miscellaneous donation of reproductive, endocrine, and metabolic abnormalities. It involves dislocation of the hypothalamic- pituitary- ovarian axis and androgen excess, which distinguish it from other causes of ovulatory dysfunction. Encyclopedically, PCOS affects roughly 6 – 13 of women, making it the most common endocrine complaint in this population. Despite its high frequence, up to 70 of cases remain undiagnosed, which underscores the significant challenge in early identification and operation. The pattern carries pitfalls beyond reproductive health, contributing to increased prevalence of metabolic pattern and habitual inflammation. 1 Women with PCOS commonly experience varied symptoms that impact both their reproductive health and overall well-being. Menstrual irregularities such as infrequent, prolonged, or absent periods are characteristic, resulting from disrupted ovulation. Additionally, many patients present with signs of hyperandrogenism—excess male hormones—which cause physical manifestations like unwanted facial and body hair growth (hirsutism), acne, and hair thinning or loss. Infertility is a frequent outcome of these reproductive disruptions, often leading women to seek medical assistance. On the metabolic front, insulin resistance and weight gain, particularly around the abdomen, are frequently observed, even in women with a normal body mass index, further complicating the clinical picture.2 Beyond its immediate symptoms, PCOS significantly elevates the risk of serious long-term health problems. The insulin resistance frequently seen in PCOS contributes to a higher likelihood of developing type 2 diabetes mellitus, with affected women facing greater challenges in glucose regulation. Cardiovascular risk is also increased due to associated conditions like hypertension, abnormal cholesterol levels, and systemic inflammation. Additionally, reproductive complications such as increased rates of infertility, miscarriage, and risks associated with pregnancy further burden affected individuals. Consequently, PCOS demands attention not only as a reproductive disorder but also as a chronic metabolic condition with systemic implications3.Treating PCOS effectively requires more than medication alone; comprehensive strategies integrating lifestyle and pharmacological interventions are essential. Weight management through healthy diet and regular physical activity improves insulin sensitivity and hormonal profiles and reduces many symptoms. While medications like metformin and ovulation-inducing agents aid in addressing metabolic and fertility issues, they often work best when combined with sustained lifestyle changes. Novel therapies, such as GLP-1 receptor agonists, have demonstrated potential in enhancing weight loss and metabolic control, especially when used alongside traditional treatment. Addressing psychological well-being through counseling or support groups is likewise crucial, highlighting the necessity of multidisciplinary care models 4.Although significant progress has been made in understanding and managing PCOS, critical research gaps remain, especially regarding individualized treatment approaches. The syndrome’s heterogeneity means that one-size-fits-all therapies are unlikely to be fully effective. Future research must focus on unraveling the genetic, molecular, and environmental factors influencing phenotypic variation. Additionally, the psychological and social dimensions of PCOS require further exploration to develop comprehensive care plans. International collaborations aimed at setting standardized research priorities and outcome measures promise to speed advances, but ensuring patient involvement in shaping research agendas is vital. Ultimately, advancing PCOS care hinges on integrating scientific discovery with personalized, holistic treatment strategies5.
PATHOPHYSIOLOGY OF PCOD
The pathophysiology of hormonal imbalance in PCOS is multifaceted, primarily involving dysregulation of the hypothalamic-pituitary-ovarian (HPO) axis. In women with PCOS, there is an abnormal increase in the frequency of gonadotropin-releasing hormone (GnRH) pulses from the hypothalamus, which leads to an increased secretion of luteinizing hormone (LH) relative to follicle-stimulating hormone (FSH). The elevated LH levels stimulate theca cells in the ovaries to produce excess androgens, such as testosterone and androstenedione. This hyperandrogenism manifests clinically as hirsutism, acne, and hair thinning, and contributes directly to disrupted follicular development. The increased androgens interfere with normal folliculogenesis, resulting in the arrest of follicle maturation and ovulation, leading to prevalent in many women with PCOS—plays a significant role by elevating circulating insulin levels, which enhance ovarian androgen production through direct stimulation of the ovarian theca cells. Furthermore, high insulin levels decrease the hepatic synthesis of sex hormone-binding globulin (SHBG), increasing the free, bioactive form of androgens in the circulation. The hormonal imbalance also disturbs estrogen levels, particularly estradiol (E2), which affects endometrial function and menstrual regularity. Additionally, the altered neuroendocrine environment, characterized by disrupted cortisol and cytokine levels, further exacerbates the imbalance, promoting chronic low-grade inflammation that can worsen insulin resistance and androgen excess. This complex interplay of neuroendocrine, metabolic, and ovarian factors creates the characteristic features of PCOS, including irregular menstruation, anovulation, and hyperandrogenism, and underpins its diverse symptomatology and comorbidities.3
PCOS, insulin resistance leads to hyperinsulinemia, which lowers SHBG levels and directly stimulates ovarian androgen production, resulting in hyperandrogenism. Elevated androgens then contribute to abdominal fat deposition, which worsens insulin resistance, creating a vicious cycle. At the cellular level, this resistance is linked to defective insulin receptor signaling with increased serine phosphorylation and reduced tyrosine phosphorylation, impairing the PI3K–glucose transport pathway. In addition, newer studies suggest that microRNA dysregulation (e.g., miR-122), gut microbiota imbalance with reduced autophagy, mitochondrial dysfunction, oxidative stress, and ER stress also play important roles in the development of insulin resistance and ovarian dysfunction in PCOS.4
The document emphasizes that discovery research, including genetic and molecular analyses, is crucial for understanding the underlying causes and mechanisms of PCOS. Although detailed genetic factors are not extensively discussed in the clinical research roadmap, it highlights the importance of consolidating data across studies, including clinical, genetic, and epigenetic data, to better understand the multifaceted nature of PCOS and its diverse manifestations across different populations and life stages .Specifically, integrating genetic data can help identify subtypes of PCOS and potential personalized intervention targets, contributing to the advancement of precision medicine. However, the document notes that discovery science, including genetics, remains a separate priority area, not the primary focus of the current clinical research roadmap, which centers on immediate clinical care needs.6
pathophysiology of PCOS substantially by adding insulin resistance and hyperinsulinemia. Redundant fat, especially abdominal fat, leads to disabled insulin signaling, which causes the pancreas to produce further insulin. High insulin situations stimulate the ovaries to produce further androgens and reduce coitus hormone-binding globulin (SHBG), adding free testosterone situations. This hyperandrogenism contributes to PCOS symptoms like irregular ovulation and hypertism. Rotundity also causes low-grade inflammation and changes in fat towel function that further worsen insulin resistance and androgen excess. Together, these factors produce a vicious cycle that intensifies the metabolic and reproductive abnormalities seen in PCOS. Weight loss can help break this cycle by perfecting insulin receptivity and lowering androgen situations7
PHARMACOLOGICAL STRATEGIES
Oral contraceptive pills (OCS) are commonly used to regulate menstrual cycles and reduce hyperandrogenism in women with PCOS. They work by suppressing luteinizing hormone (LH) levels, decreasing ovarian androgen production, and increasing sexual hormone-binding globulin (SHBG) levels, which help reduce free testosterone levels. Despite their effectiveness, OCS carry potential risks such as thromboembolism, metabolic disturbances, and other side effects, which should be carefully considered when prescribing them for long-term management.8
Anti-androgens such as spironolactone, flutamide, and finasteride are used to treat hirsutism and acne in women with PCOS by antagonizing androgen effects. However, their use is associated with safety concerns: spironolactone may cause hyperkalemia and menstrual irregularities and is teratogenic; flutamide poses a risk of hepatotoxicity requiring liver monitoring; finasteride is teratogenic and can cause decreased libido and erectile dysfunction. These medications should be prescribed carefully, with appropriate contraception and monitoring, to ensure safety during treatment.8
Insulin sensitizers are commonly employed in managing PFAS-related metabolic disturbances. Metformin is considered the gold standard due to its efficacy in improving insulin sensitivity, reducing hyperinsulinemia, and addressing reproductive and metabolic symptoms in PCOS patients. Thiazolidinediones, such as pioglitazone, also enhance insulin sensitivity but are used less frequently because of concerns related to adverse effects, including weight gain, edema, and potential cardiovascular risks. Their use in PCOS is generally limited and requires careful monitoring.8
Inositols, specifically Myoinositol and D-Cairo-inositol, are being recognized more and more for their effects on women with PCOS. Contemporary clinical trials show that treatment with these inositol can have beneficial effects on fertility and insulin sensitivity and thus appear to be promising adjuncts to the treatment of PCOD-associated reproductive and metabolic dysfunction.8
THERAPEUTIC STRATEGIES (BEYOND DRUGS)
Lifestyle modifications are considered a cornerstone in the management of PCOS, as they have the potential to address various metabolic and reproductive symptoms associated with the syndrome. Research indicates that dietary interventions focusing on balanced nutrition and reduced caloric intake can lead to improvements in insulin sensitivity and hormonal regulation, which are crucial for symptom control. Regular physical activity, including aerobic and strength training exercises, has been shown to enhance body composition, cardiovascular health, and metabolic function, thereby reducing the severity of clinical manifestations such as hyperandrogenism and irregular menstruation. Notably, even modest weight loss—around 5-10%—can significantly improve ovulatory function and insulin resistance, highlighting the importance of weight management strategies. Additionally, lifestyle changes positively impact mental health by reducing stress and improving self-esteem, which are often compromised in women with PCOS, However, gaps remain in standardized tools for assessing lifestyle factors comprehensively, and further research is needed to explore the psychosocial dimensions influencing the syndrome, including stress, body image concerns, and social interactions , Overall, integrating dietary, physical activity, and psychosocial interventions offers a holistic approach to managing PCOS, emphasizing the need for increased awareness and tailored lifestyle programs to improve health outcomes in affected women.7,8
Bariatric surgery has been identified as an effective intervention for morbidly obese women suffering from PCOS, primarily because significant weight loss resulting from such procedures can improve hormonal imbalances, ovulation, and metabolic parameters associated with PCOS. The surgery aids in reducing obesity-related insulin resistance and hyperandrogenism, thereby restoring menstrual regularity and enhancing fertility prospects. Besides bariatric procedures, alternative complementary therapies such as acupuncture and nutraceutical have been explored for managing PCOS symptoms. However, the current scientific evidence supporting their efficacy remains limited and inconclusive, indicating the need for further rigorous research to establish their potential benefits convincingly. Overall, weight management through surgical and lifestyle interventions remains a cornerstone in the management of PCOS, while supplementary treatments require more validation.8
The combination therapy approach, involving pharmacological treatments alongside lifestyle modifications, is considered to provide the best long-term outcomes for managing PCOS. Specifically, the use of oral contraceptive pills (OCP) combined with Metformin has been advocated to regulate menstrual cycles, decrease androgen levels, and improve insulin sensitivity. Additionally, strategies such as weight loss combined with the administration of GLP-1 analogs have shown promising results in addressing both metabolic and reproductive aspects of PCOS, resulting in better symptom control and potentially reducing the risk of complications associated with the syndrome. This integrated approach emphasizes the importance of targeting multiple underlying factors through combined therapies for optimal management.9
RECENT ADVANCE & CLINICAL TRIALS
Letrozole is increasingly preferred over Clomiphene for ovulation induction in women with PCOS due to its superior effectiveness in achieving live births, as trials indicate higher ovulation rates and improved pregnancy outcomes with Letrozole. Furthermore, it boasts a better side effect profile, with fewer adverse effects reported, such as hot flashes and mood swings, and a lower incidence of multiple pregnancies, making it a safer choice for women trying to conceive. Patient preference studies suggest that many women favor Letrozole over Clomiphene, attributing this preference to its favorable side effects and effectiveness, which leads to higher satisfaction rates among patients undergoing treatment for infertility. In summary, Letrozole is often the preferred option for ovulation induction in women with PCOS due to its higher effectiveness, better tolerability, and reduced risk of multiple pregnancies.10
GLP-1 receptor agonists are effective for weight management in obese patients with PCOS, promoting significant weight loss when used alongside lifestyle interventions. These medications not only aid in weight reduction but also improve metabolic parameters, such as blood glucose control and lipid profiles. However, it is essential to ensure effective contraception during treatment due to insufficient safety data regarding their use in pregnancy. Patients may experience common gastrointestinal side effects, including nausea and vomiting, so a gradual dose escalation is recommended to mitigate these effects. Additionally, patients should be informed about the potential for weight regain after discontinuation of the medication and the lack of long-term safety data.10
Recent studies have highlighted the potential advantages of using combinations of myo-inositol and D-chiro-inositol in the management of conditions like polycystic ovary syndrome (PCOS). These combinations may lead to improved insulin sensitivity and better metabolic outcomes compared to using single forms of inositol. However, the current body of evidence is still inconclusive, and there are no established clinical guidelines regarding the optimal types, dosages, or combinations of inositol that should be used for effective treatment. Further research is needed to clarify these aspects and to determine the most effective protocols for patients.10
Recent research focuses on precision medicine—tailoring PCOS treatment based on genetic, metabolic, and hormonal profiles, recognizing the heterogeneity of the syndrome. Genetic and pharmacogenomic studies may soon allow for more individualized treatment and prediction of drug response, improving long-term outcomes.11
CHALLENGES IN MANAGEMENT
The side effects of drugs used in obesity treatment, emphasizing that while these medications can aid in weight loss, they often come with significant adverse effects. For instance, Orbital, the only FDA-approved long-term obesity treatment, is associated with gastrointestinal issues such as oily stools and flatulence, which can deter patients from adhering to the treatment. Furthermore, other weight-loss medications may present unacceptable risk profiles, including cardiovascular risks or potential for dependency, which complicates their use and limits their overall effectiveness in managing obesity.12 Antiandrogens similar as spironolactone may beget side goods including gynecomastia, menstrual irregularities, and the eventuality for hepatotoxicity. Metformin generally leads to gastrointestinal symptoms like nausea, puking, and diarrhea. Combined oral contraceptive capsules (Corps) can increase the threat of venous thromboembolism, particularly with advanced boluses of estrogen, and may also affect weight gain, mood changes, and headaches. Anti-obesity medicines, similar as GLP- 1 receptor agonists, constantly beget gastrointestinal issues such as diarrhea, nausea, and puking, and presently there is limited long-term safety data available. Antiandrogens like cyproterone acetate, when used for dragged ages, may be associated with an advanced threat of meningioma and other side goods including weight gain and fluid retention.10
Poor adherence to lifestyle changes poses a significant challenge in managing PCOS, as it often diminishes the potential benefits of interventions like diet, exercise, and behavioral modifications. Despite their crucial role in improving metabolic health, hormonal balance, and fertility outcomes, many women find it difficult to sustain these changes over time. This difficulty can be attributed to factors such as lack of motivation, insufficient support, difficulties in changing established habits, and possible health system limitations in providing ongoing guidance. Recognizing these barriers, the guidelines emphasize the importance of a patient-centered approach that incorporates education, empowerment, and shared decision-making to enhance adherence. Providing tailored advice, regular monitoring, and addressing individual concerns are key strategies to improve long-term compliance with lifestyle modifications in women with PCOS.10
The lack of standardized global guidelines for PCOS diagnosis and management results in significant variability in clinical practices and patient outcomes. Differences arise from varying diagnostic criteria, such as reliance on ultrasound versus serum anti-Mullein hormone (AMH) levels, and diverse treatment preferences. Ultrasound interpretation can be subjective and affected by equipment quality and operator experience, whereas AMH offers a more stable and objective biomarker correlated with follicular count and PCOS severity. However, limitations in AMH assay standardization and the absence of universally accepted cut-offs hinder its full adoption as a diagnostic tool. Additionally, differences in healthcare infrastructure, cultural factors, and resource availability further contribute to inconsistent PCOS care worldwide. International efforts like the 2023 International Evidence-based Guideline aim to unify diagnostic criteria and treatment approaches with a holistic, patient-centered framework, promoting early diagnosis, effective treatment, and consistent monitoring. Such standardized evidence-based guidelines are essential to reduce diagnostic delays, improve treatment outcomes, and ensure equitable care for women with PCOS globally.10
Variability in drug response is recognized in the management of PCOS, influenced by factors such as individual metabolic profiles, presence of obesity, and specific symptomatology. For instance, metformin tends to have more pronounced effects on weight and metabolic outcomes in women with higher BMI (greater than 25 kg/m²), while similar benefits may be less evident in leaner women. Additionally, the effectiveness of anti-androgens for hyperandrogenic symptoms can vary depending on the severity of symptoms and patient-specific factors. Inositol's benefits are uncertain and may differ among individuals, partly due to variation in absorption and regulation. Furthermore, response to anti-obesity drugs like orbital and GLP-1 receptor agonists can differ based on baseline BMI, adherence, and other metabolic factors. This variability underscores the importance of personalized, patient-centered treatment plans, with ongoing monitoring to optimize outcomes.10
FUTURE DIRECTIONS
There has been a growing interest in single nucleotide polymorphism (SNPs) and their implicit for prognosticating individual medicine response. In the near future, with pharmacogenomics advances, it may be possible to define specific medicines with precise capsules rested on the SNP profile, reducing bane and boosting treatment effectiveness. The pharmacological treatment of women with PCOS is substantially acquainted to lessen metabolic abnormalities and to restore fertility. The generally specified medicines include metformin, camphene citrate (CC), oral contraceptives capsules (OCP), follicle stimulating hormone (FSH) among others. Medicine resistance, side goods, undetermined capsule for favorable results and bane in seed have been reported in treated women with PCOS. Having a collection of SNPs conferring PCOS vulnerability and medicine response will contribute to developing a gene score for trouble visualizations and substantiated treatments. Despite efforts to use monotherapy or combination remedy to meliorate PCOS symptoms, responses are variable, and the determinants of this inconsistency remain fugitive. Variability in PCOS effectiveness treatment has been suspected to be associated with gene-treatment relations. Piecemeal from medicine response variability, 30 women with PCOS didn't respond to metformin and 15 to 40 are CC resistance after entering 150 mg/day. There is confirmation that genes polymorphisms might be predictors for medicine resistance, emphasizing the connection of pharmacogenomics studies in PCOS.13
Future research should focus on conducting long-term, large-scale randomized controlled trials to thoroughly evaluate the safety and efficacy of GLP-1 receptor agonists and inositols in women with PCOS. These studies should include extended follow-up periods to monitor potential cumulative adverse effects and long-term outcomes on reproductive health, metabolic profile, and overall well-being. Additionally, robust post-marketing surveillance programs are necessary to identify rare or unforeseen adverse events associated with prolonged therapy. Particular attention should be given to investigating possible risks such as gastrointestinal disturbances, pancreatic, thyroid, or cardiovascular issues linked to GLP-1 receptor agonists, as well as hormonal and ovarian function impacts related to inositol supplementation. Incorporating personalized treatment strategies based on individual risk profiles will enhance safety and treatment effectiveness. Furthermore, understanding the underlying mechanisms through molecular and cellular research can reveal insights that contribute to developing safer, targeted therapies. Establishing patient registries and collecting real-world evidence will also be vital for ongoing safety monitoring and optimizing long-term management protocols for women with PCOS.14
Recent advancements in therapeutic agents for PCOS are focusing on targeting the central neuroendocrine regulators that drive the disorder. Neurokinin-3 receptor (NK3R) antagonists are among the most promising new agents; they act by inhibiting neurotoxin B signaling within the hypothalamic arcuate nucleus, which can lower GRH pulse frequency and consequently reduce LH hypersecretion. This approach aims to correct the hormonal imbalance at its source, potentially normalizing androgen levels and restoring ovulation. Additionally, modulators of kisspeptin signaling are being developed to regulate downstream inputs to GRH neurons, offering another pathway to improve reproductive function. Advances in long-acting GRH analogues and receptor modulators with improved pharmacokinetic profiles are also under investigation, aiming to provide more stable suppression of gonadotropin secretion with fewer side effects. Furthermore, innovative drug delivery systems like nanoparticles are being explored to enhance targeting accuracy and treatment efficacy while minimizing systemic exposure. Collectively, these newer agents strive to intervene earlier and more precisely in the neuroendocrine cascade responsible for PCOS, potentially leading to more effective and personalized therapies in the future.15
CONCLUSION
Polycystic ovary syndrome (PCOS) is a common and multifactorial disorder with reproductive, metabolic, and psychological implications, requiring more than single?line therapy. Its complex pathophysiology—rooted in hormonal imbalance, insulin resistance, and genetic and environmental factors—necessitates both pharmacological and therapeutic strategies for optimal outcomes. Pharmacological options remain central to management. Oral contraceptives regulate cycles and reduce androgen excess, while anti?androgens provide relief from hirsutism and acne. Metformin continues to be widely used to improve insulin sensitivity, and letrozole has replaced clomiphene as the preferred first?line ovulation induction agent. Recent evidence also supports the benefits of inositols and GLP?1 receptor agonists in improving metabolic profiles and fertility outcomes, signaling a shift toward more targeted therapy. Beyond medication, lifestyle interventions such as diet modification, exercise, and weight reduction remain key to long?term success, with even modest weight loss improving ovulation and metabolic health. In certain cases, bariatric surgery or adjunctive strategies may be considered. Importantly, combining pharmacological therapies with sustainable lifestyle measures consistently offers the best long?term results. Despite these advances, challenges such as drug side effects, poor adherence to lifestyle changes, and lack of standardized global guidelines continue to hinder management. Looking ahead, precision medicine—through pharmacogenomics, individualized treatment plans, and newer agents—holds potential to refine therapy further. In summary, PCOS management must be comprehensive and multidisciplinary, integrating pharmacological treatments with lifestyle modification. Advances in current therapies and future developments promise more effective, personalized care, ultimately improving reproductive and metabolic outcomes for women with PCOS.
REFERENCES
Tarnnum Shaikh, Tejal Anarthe, Pharmacological and Therapeutic Strategies for Polycystic Ovary Syndrome: Advances and Future Directions, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 11, 1829-1838. https://doi.org/10.5281/zenodo.17589985
10.5281/zenodo.17589985
